Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06592261 · ClinicalTrials.gov registry record · Phase 1
Graded Insulin Suppression Test P&F
A Phase 1 study of Healthy and Obesity, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT06592261 is a Phase 1 study of Healthy and Obesity that is actively recruiting participants, run by Columbia University. The registered enrollment target is 15 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06592261, a Phase 1 study of Healthy and Obesity, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. Participants will be asked to come in for a one-day study visit in which they will undergo a "graded insulin suppression test" ("GIST"). The GIST involves intravenous (into the vein) infusions of octreotide, a medication that turns off the body's own production of insulin, as well as replacement of insulin at two different levels (low and high), with or without replacement of glucagon, and glucose (sugar). The study investigators will check blood sugar levels every few minutes during the procedure to determine the effect of the two different insulin levels. This study will evaluate the GIST in both healthy volunteers and those at higher risk for type 2 diabetes.
Conditions Studied
Interventions
- DRUG Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia)
- DRUG Insulin regular, 32 mU/m2/min (hyperinsulinemia)
- DRUG Octreotide Acetate, 6-45 ng/kg/min
- DRUG Dextrose 20 % in Water
- DRUG Glucagon, 0-0.5 ng/kg/min
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-09-16 |
| Est. Completion | 2026-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06592261
The ClinicalTrials.gov registry entry for NCT06592261 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Healthy appearing as the primary indexed condition, and to 5 interventions - of which Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia) is the first listed.
NCT06592261 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06592261 about?
NCT06592261 is a clinical study titled "Graded Insulin Suppression Test P&F". The goal of this study is to learn about how the hormone insulin controls blood sugar in a variety of people. The main question it aims to answer is about how much insulin the body actually needs to maintain a normal blood sugar level. Participants will be asked to come in for a one-day study visit ...
What is the current status of trial NCT06592261?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2024-09-16. Estimated completion is 2026-08.
What conditions does trial NCT06592261 study?
This clinical trial studies the following conditions: Healthy, Obesity, Insulin Resistance, Hyperinsulinemia.
What interventions are being tested in trial NCT06592261?
The interventions under investigation include: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia) (DRUG), Insulin regular, 32 mU/m2/min (hyperinsulinemia) (DRUG), Octreotide Acetate, 6-45 ng/kg/min (DRUG), Dextrose 20 % in Water (DRUG), Glucagon, 0-0.5 ng/kg/min (DRUG).
Who is sponsoring clinical trial NCT06592261?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06592261 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.